Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Clinical trial NCT04643379 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04643379
Sponsor: Washington University School of Medicine
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Head and Neck Squamous Cell Carcinoma Metastatic Head and Neck Squamous Cell Carcinoma

Start date: 2021-08-07
Primary completion: 2025-10-16
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.